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         Interleukin-8 (IL-8) is a chemokine whose primary function is to regulate neutrophil 
chemotaxis and modulate the inflammatory response in normal physiologic conditions.  
Additionally, IL-8 appears to play an important role in tumorigenesis and metastasis in vitro and 
in vivo in human solid tumors.  There is growing evidence to suggest that IL-8 can serve as a 
biomarker for patients with cancer, with high IL-8 levels often correlated with advanced stage 
disease, metastasis, and poorer overall outcome.  Though IL-8 appears to be intimately 
associated with cancer progression and metastasis in human, the role of IL-8 in veterinary 
oncology is largely unexplored. 
Osteosarcoma (OS) is a common, naturally-occurring, highly metastatic cancer in dogs 
that serves as an excellent model for the disease in people.  Recent comparative genomics 
indicate that IL-8 expression is conserved in both human and canine OS and is a negative 
prognostic indicator in people with this cancer.  Therefore, understanding how IL-8 impacts 
disease progression, specifically in regards to the development of metastasis, could help us more 
effectively manage OS in both dogs and people. 
In this study, we hypothesized 1) that canine OS cells will express IL-8 and its cognate 
receptors, CXCR1 and CXCR2, 2) that inhibition of IL-8 signaling will attenuate proliferation 
and migration, 3) that inhibition of IL-8 signaling will enhance sensitivity to cytotoxic agents, 
and 4) that IL-8 signaling will influence the expression of genes involved necessary for 
angiogenesis. 
We investigated CXCR1 and CXCR2 gene transcription with qualitative polymerase 
chain reaction (PCR), and we investigated protein expression for IL-8, CXCR1, and CXCR2 
with Western blotting.  We evaluated OS cell production of IL-8 with an ELISA.  We employed 
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a competitive CXCR1/CXCR2 antagonist (Reparixin), as well as an IL-8 neutralizing 
monoclonal antibody (mAb), to mitigate IL-8 signaling in cell lines. Fluorescent cellular 
metabolic assays were used to determine the effects of manipulation of the IL-8 signaling axis on 
cellular proliferation and on chemosensitization to a platinum chemotherapeutic (carboplatin).  
Scratch assays were used to assess cellular migration following exposure to one of the IL-8 
inhibitory agents.  Quantitative PCR was again used to evaluate the gene transcription of VEGF 
in OS cell lines and a canine endothelial cell line following manipulation of the IL-8 signaling 
axis. 
Gene transcription of the IL-8 receptors was noted in six OS cell lines.  Furthermore, we 
were able to demonstrate protein expression of IL-8 in all cell lines.  IL-8 was produced in a cell 
density-dependent manner in all cell lines examined.  We showed that the addition of exogenous 
IL-8 led to a dose-dependent increase in proliferation in an OS cell line that was a low producer 
of IL-8.  IL-8 receptor blockade appeared to have no impact on proliferation at the doses 
examined.  IL-8 receptor blockade also did not enhance sensitivity to carboplatin in vitro. 
However, receptor blockade did appear to inhibit migration in a dose-dependent manner in the 
low-producer of IL-8.  IL-8 neutralization with a mAb had not effect on proliferation, migration, 
or chemosensitization.  We were also able to show that addition of IL-8 increased VEGF gene 
transcription. 
These findings suggest that autocrine/paracrine IL-8 signaling may be more important in 
promoting a more metastatic cellular phenotype in those OS cells that are low-producers of this 
chemokine.  Additionally, our results suggest that IL-8 likely plays a role in cultivating a pro-
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Interleukin-8 (IL-8) is a chemokine that is essential in normal inflammatory physiology.  
Specifically, IL-8 appears to primarily mediate neutrophil chemotaxis and degranulation.  When 
released, IL-8 binds to two transmembrane G-protein coupled receptors, known as CXCR1 and 
CXCR2.  Although the highest density of CXCR1 and CXCR2 are found on inflammatory cells 
like neutrophils and macrophages, IL-8’s cognate receptors are also expressed by normal 
epithelium and endothelium.  Signaling through these receptors on inflammatory cells typically 
results in perpetuation of the inflammatory response through stimulation of the respiratory burst 
of neutrophils and upregulation of IL-8 and other pro-inflammatory cytokines (1–4).  However, 
in tissue cells, IL-8 signaling appears to have more pleiotropic effects.  For example, 
proliferation pathways, like the mitogen activated protein kinase (MAPK), are often upregulated 
as a result of IL-8 binding to its receptors.  Furthermore, IL-8 signaling appears to be intimately 
associated with the stimulation of angiogenesis – a process essential in perpetuation and 
resolution of the normal inflammatory response (5,6). 
Stimulation of proliferative pathways, induction of angiogenesis, and resistance to cell 
death are features that have been recognized as classic “hallmarks” of cancer generation and 
success.  More recently, promotion of an inflammatory microenvironment has also been 
considered a hallmark (7).  As IL-8 signaling results in upregulation of several commonly 
upregulated signaling pathways considered paramount to the development of cancer and 
metastasis, it is not surprising that IL-8’s role in cancer has been heavily researched since it was 
first described.  In vitro data has consistently identified the over-expression of IL-8 and 
associated signaling in a variety of human solid and hematopoietic tumor cell lines.  
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Furthermore, aberrant IL-8 expression and signaling appears to endow these cancer cells with a 
potentially enhanced metastatic phenotype (8–11).  Clinical research has proven that IL-8 is a 
useful prognostic marker in some solid tumor settings, and patients with increased tumoral 
expression of IL-8 or increased serum IL-8 typically have poorer outcomes (12–16).  Research 
into targeting IL-8 and its signaling axis is growing as personalized cancer treatment is proving 
to be more relevant.  Unfortunately, neutralizing monoclonal antibodies against IL-8 have proven 
ineffective in cancer management, to date.  However, IL-8 receptor inhibition therapy shows 
promise and clinical trials are ongoing (1,17).  
Little is known about IL-8 expression in animals with spontaneously occurring solid 
tumors.  As dogs develop several types of solid tumors that serve as good models for certain 
human tumors, it is logical to hypothesize that IL-8 expression and signaling might be a 
contributing factor to the development and progression of some tumors in dogs.  As IL-8 
expression has been linked to an aggressive biologic behavior and the development of metastases 
in human cancers, it could also be hypothesized that highly metastatic cancers in dogs would be 
best suited for preliminary investigation into IL-8 expression and signaling.   
Osteosarcoma, a commonly diagnosed primary bone tumor, is one such highly metastatic 
canine cancer.  Approximately 90% of patients with this disease will succumb to pulmonary 
metastatic disease, with the majority dying within a year of diagnosis (18–21).  Little 
advancement has been made in prolonging time to metastasis and survival in the past couple of 
decades, so it is apparent that additional strategies are needed to prevent the development of 
metastases in our veterinary patients with osteosarcoma.  Recently, comparative genomic 
analysis between spontaneously occurring osteosarcomas in people and in dogs showed a shared 
gene expression profile in these species.  IL-8, which was consistently overexpressed in canine 
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samples, was less frequently expressed in human samples.  However, it was proven that, when 
IL-8 was expressed in humans, those patients had a significantly poorer outcome (22).  From 
these findings, it was hypothesized that IL-8 signaling plays an important role in osteosarcoma 
metastases in both people and in dogs.  Providing a better understanding as to how IL-8 and it 
signaling axis influence the metastatic potential of osteosarcoma would likely result in treatment 
avenues better suited to control disease progression in both people and in dogs.  
The purpose of this study was to investigate the role of IL-8 in the development of 
spontaneous metastasis in dogs with appendicular osteosarcoma (OS).  The specific aims of this 
study were 1) to characterize the expression of IL-8 and its cognate receptors, CXCR1 and 
CXCR2, in four OS cell lines; 2) to establish cell propagation, survivability, and migration in 
vitro with or without CXCR1/CXCR2 inhibition; and 3) to characterize VEGF gene expression 
in OS cell lines after manipulation of the IL-8 signaling axis.  We hypothesized 1) that IL-8 
signaling promotes canine OS cell metastases through an autocrine or paracrine manner; 2) that 
inhibiting IL-8 signaling in canine OS cells will attenuate cell proliferation, impair cell 
migration, and increase cell susceptibility to DNA-damaging agents; and 3) that IL-8 signaling 








2.1.1 Interleukin-8 is a chemokine 
Chemokines are cytokines specifically involved in the concentration-dependent migration 
(chemotaxis) of leukocytes in the body (2–4).  Chemokines are small proteins, typically less than 
11 kilodaltons (kDa) in length (2).  Chemokines are cysteine-rich proteins and are classified into 
four families by the location of the cysteine residues within the protein itself (1,3).  Interleukin-8 
(IL-8) or CXCL8 is in the cysteine-X-cysteine (CXC) family of chemokines, which all contain a 
single amino acid between the first and second cysteine residues (4,5,23).  The IL-8 protein is 
translated as an inactive protein that is 99 amino acids (aa) in length (5,6).  Post-translational 
modification of this protein in leukocytes and in non-immune cells (endothelium and fibroblasts) 
results in active proteins, 72 aa and 77 aa in length (roughly 8 kDa), respectively (5,6).  IL-8 was 
first described in 1989 as a pro-inflammatory chemokine that appeared to be an important 
regulator of neutrophil chemotaxis and degranulation (24).         
 
2.1.2 IL-8 gene expression 
IL-8 gene expression appears to be dependent on the co-expression of transcription 
factors nuclear factor-κB (NF-κB) and activator protein 1 (AP-1) (5,25).  IL-8 gene expression is 
upregulated in response to various inflammatory stimuli like physical cellular trauma, exposure 
to bacterial or viral components, and increased concentrations of other inflammatory signals like 
interleukin-1 (IL-1), interferon-γ (IFN- γ) and tumor necrosis factor-alpha (TNF-α) (5,6,26–28).  
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Environmental stressors like hypoxia, hyperosmolarity, acidic pH, cell density, nitric oxide 
concentration, and reactive oxygen species (ROS) exposure also influence IL-8 gene expression 
(27,29).  Ligand binding to cellular death receptors, like Fas, has also been shown to upregulate 
gene expression of IL-8 through NF-κB activation (30). 
 
2.1.3 Cellular receptors for IL-8: CXCR1 and CXCR2 
Chemokine signaling, and ultimately the biologic effect of chemokines, is initiated by 
chemokine binding to a transmembrane receptor (3–5,31–33).  The four distinct families of 
chemokines bind to their own distinct family of guanine-protein coupled receptors (GPCRs) 
(4,32).  Seven distinct CXC chemokine GPCRs, which typically bind multiple CXC chemokines, 
have been identified to date (4).  However, IL-8 exclusively binds to two CXC GPCRS: CXC 
chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2) (3,31–33).  CXCR1 
and CXCR2 are found in highest density on mature neutrophils and monocytes.  However, other 
white blood cells, like T lymphocytes, mast cells, eosinophils, and dendritic cells, also express 
CXCR1 and CXCR2 (31,34).  In addition to hematopoietic cells, IL-8 receptor expression is 
noted on various types of epithelium and endothelium (28,31).  Expression on neoplastic cells, 
like carcinoma, sarcoma, and cancer stem cells, is also well-documented and will be discussed in 
greater detail later (3,4,6,23,32).   Of the two IL-8 receptors, CXCR1 is a more selective 
receptor, only binding IL-8 and IL-6.  The more promiscuous CXCR2 binds IL-1, IL-2, IL-3, IL-
5, IL-5, and IL-7, in addition to IL-8 (4,32,33,35).  
Upon IL-8 binding to either CXCR1 or CXCR2, the GPCR undergoes a conformational 
change and guanosine diphosphate (GDP) bound to the G protein on the inner surface of the cell 
membrane is exchanged for guanosine triphosphate (GTP).  Exchange of GDP for GTP causes 
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the Gα subunit of the G protein to dissociate from the Gβγ subunit (5,32,36).  These subunits go 
on to initiate a variety of signaling pathways that play an important role in both inflammation 
and cancer metastasis, a subset of which are mentioned later.   
Although the CXCR1 and CXCR2 proteins are highly homologous, the literature 
suggests that functions of these receptors are disparate (31).  Inhibition of CXCR1 dramatically 
inhibits production of the superoxide anion by neutrophils in vitro, whereas inhibition of CXCR2 
has minimal effect on superoxide (37).  This finding is suggestive that signaling through 
CXCR1, alone, allows for the respiratory burst of neutrophils.  CXCR2 has been described to be 
important in regulating neutrophil release from the bone marrow, as well as the generation of 
neutrophil extracellular traps (NETs) (38,39). 
 
2.2 IL-8 in the normal inflammatory response and malignancy 
 
2.2.1 IL-8 and cellular proliferation 
 The ability of a cell to continuously proliferate is an identified hallmark of cancer (7).  
IL-8 is a known mitogen, and increased IL-8 concentrations result in increased cellular 
proliferation in normal epithelium, normal endothelium, and a variety of cancer cells.  Exposure 
of keratinocytes to physiologic concentrations of IL-8 in vitro results in significantly increased 
cell proliferation when compared to control conditions (40).  Moreover inhibition of IL-8 with a 
polyclonal anti-IL-8 antibody significantly decreased cell proliferation (40).  Dose-dependent 
increases in cellular proliferation with IL-8 have also been documented in human umbilical vein 
endothelial cells (HUVEC), human dermal microvascular endothelial cells (HMEC), and 
melanocytes in vitro (41–43).  An experimental model of wound healing in vivo demonstrated 
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that topical application of IL-8 to a wound enhanced wound re-epithelialization, diminished 
wound contraction, and significantly increased the mitotic index of keratinocytes within the 
wound bed when compared to wounds not treated with IL-8 (44).  This preliminary research is 
pivotal because it not only laid the foundation for IL-8 as a stimulant for cell proliferation, but 
also, it established that autocrine and/or paracrine cellular signaling through IL-8 could alter the 
cellular microenvironment. 
 
2.2.1.1 IL-8 and cellular proliferation in neoplasia 
 Shortly after the discovery of IL-8’s impact on normal cellular proliferation, focus was 
shifted toward examining IL-8 expression and production by neoplastic cells.  Zachariae et al. 
were the first group to document IL-8 production by human melanoma cells and to theorize that 
this chemokine was important for tumor growth (43,45).  Further work in human melanoma (46), 
ovarian carcinoma (47), pancreatic carcinoma (48,49), colonic carcinoma (50), non-small cell 
lung cancer (NSCLC) (51), and prostatic carcinoma (52) cell lines confirmed that addition of IL-
8 to cell culture significantly increased proliferation in vitro.  Moreover, expression of IL-8 in 
vitro and tumor expression of IL-8 in vivo was correlated to a more highly metastatic cancer 
phenotype (46–48,52). 
 Different mechanisms to explain IL-8 mediated cellular proliferation have been 
described.  In human neutrophils, it has been hypothesized that phosphatidylinositol 3- kinase 
(PI3-K) phosphorylation after CXCR1/CXCR2 activation by IL-8 is necessary for 
phosphorylation of the Ras/Raf/mitogen-activated protein kinase (MAPK) pathway.  The 
investigators reached this conclusion after the use of wortmannin, a non-selective inhibitor of 
PI3-K, inhibited phosphorylation of Raf and MAPK in neutrophils exposed to IL-8 (53).   
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A link between IL-8 signaling and the epidermal growth factor receptor (EGFR) has been 
proposed in endothelial (54), NSCLC (51), and ovarian cancer cell lines (55).  In the presence of 
IL-8, concurrent activation of the EGFR and MAPK enzymes was noted in these cell lines.  
Furthermore, a tyrosine kinase inhibitor of and a monoclonal antibody for EGFR inhibited the 
MAPK pathway in ovarian carcinoma and lung cancer cell lines, respectively.  Inhibition of 
EGFR and MAPK correlated with decreased cellular proliferation in vitro (51,55). 
 In prostate cancer, it has been shown that IL-8 influences the expression of cyclins and 
cyclin-dependent kinases, specifically cyclin D1 (8).  Addition of exogenous IL-8 to two 
separate prostate cancer cell lines increased expression of cyclin D1, whereas inhibition of IL-8 
and its receptors down-regulated the expression of cyclin D1.  These investigators theorized that 
IL-8-induced over-expression of cyclin D1 in prostate cancer cells leads to unregulated 
progression through the cell cycle, and a subsequent increase in cellular proliferation.  
Furthermore, these investigators also showed that IL-8 signaling through the PI3-
K/Akt/mammalian target of rapamycin (mTOR) pathway influences cellular proliferation.  Using 
small interfering RNA (siRNA) technology, inhibition of Akt and mTOR expression in the 
presence of IL-8 significantly reduced cellular proliferation in comparison to controls (8). 
 
2.2.2  IL-8 and cellular migration 
 The ability of cells to migrate and invade surrounding tissue is another recognized 
hallmark of cancer, and arguably one of the more important features of a cancer cell in regard to 
its metastatic potential (7).  In addition to stimulating neutrophil chemotaxis in the acute 
inflammatory setting, IL-8 has also been shown to promote cellular migration in endothelium, in 
the epithelium of the gastrointestinal tract, and in a variety of malignant cell lines.  Koch et al. 
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were the first to describe an association between IL-8 and chemotaxis in HUVECs by 
documenting an incremental decrease in cellular migration using increasing concentrations of an 
IL-8 antisense nucleotide (56).  Similarly, another group demonstrated that exogenous IL-8 
added to endothelial cell culture significantly enhances their migration in a dose-dependent 
manner in comparison to cells in control conditions.  Concurrent upregulation of matrix 
metalloproteinases (MMPs) by IL-8 causing degradation of extracellular matrix was a proposed 
hypothesis to explain IL-8’s role in cellular migration (41).   
However, this hypothesis was not supported in later work.  Schraufstatter et al. showed 
that migration of endothelial cells was only partially inhibited by inhibiting various MMPs.  
Rather, cathepsin B, an intracellular protease, appeared most essential to endothelial cell 
migration as inhibition of cathepsin B ablated cell migration.  These investigators went on to 
show that IL-8 binding to CXCR2 activates cathepsin B.  Cathepsin B cleaves and activates 
pericellular heparin-binding epidermal growth factor (EGF)-like growth factor, which 
transactivates the epidermal growth factor receptor (EGFR).  Subsequent downstream EGFR 
signaling through PI3K appears to be the most relevant signaling cascade in regards to 
endothelial cell migration, as inhibition of this pathway also led to inhibited migration (54). 
Additionally, it was concluded that signaling through CXCR1 did not contribute to endothelial 
cell migration in any meaningful way (54,57,58).  This was a novel finding as migration of 
neutrophils appears to be primarily mediated through CXCR1 (59,60). 
IL-8 appears to mediate epithelial cell migration in the GI tract through a different 
mechanism than the aforementioned.  In contrast to endothelial cells, CXCR2 was not expressed 
in two different intestinal epithelial cell lines, whereas CXCR1 was constitutively expressed.  
Although addition of IL-8 to cell culture did not significantly impact cell proliferation, IL-8 did 
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significantly enhance migration in a dose dependent manner.  These effects on migration could 
be mitigated, but not totally inhibited, in the presence of anti-CXCR1 antibody.  The 
investigators concluded that IL-8 signaling through CXCR1 was primarily responsible for 
intestinal epithelial cell migration but that other, more nebulous, CXCR1-independent pathways 
were also involved in regulating migration (61). 
 
2.2.2.1 IL-8 and cellular migration in neoplasia 
There are multiple mechanisms through which IL-8 induces migration in physiologically 
normal cells, so it should not be surprising that there are various described mechanism through 
which IL-8 exerts its migratory effects in cancer cells.  The migratory effects of IL-8 on cancer 
cells in vitro were first described in a human melanoma cell line (62).  Simply, IL-8 
concentration gradient-dependent migration was demonstrated along with inhibition of migration 
using anti-IL-8 antibody in this melanoma cell line.  IL-8’s migration effects on melanoma cells 
have since been corroborated.  Successful transfection of a melanoma cell line that is a low-
expressor of IL-8 with a mammalian IL-8 expression vector not only led to the overproduction of 
IL-8 in this cell line, but also enhanced migration, proliferation, and invasion (9).  Again, 
inhibition of IL-8 production using an antisense vector reduced migration and increased cell 
death as compared to control cell lines (9).  Experiments using neutralizing antibodies against 
IL-8 receptors have shown that melanoma cell migration is dependent upon CXCR2 signaling in 
vitro (63).  Migration of melanoma cells in the presence of exogenous IL-8 was significantly 
inhibited in the presence of a MEK inhibitor, suggesting that MEK activity and subsequent ERK 
phosphorylation are key (64).  IL-8 signaling through FKBP51, an immunophilin protein that is 
an important regulator of intracellular steroid receptor signaling, has also been implicated in 
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melanoma migration (65).  IL-8-mediated downregulation of the tetraspanin protein CD82 on 
melanoma cells has been implicated in mediating melanoma extravasation in endothelial cells 
(66), and an IL-8 neutralizing antibody prevented extravasation (67).   
In prostate carcinoma cell lines, intracellular signaling pathways that have been 
implicated in IL-8 induced migration in these cells include the Src kinase pathway and the focal 
adhesion kinase (FAK) pathway.  Inhibitors of Src and FAK were both able to inhibit migration 
in vitro (68).  Another group working with a prostate cancer cell line showed a three-fold 
increase in migration in the presence of IL-8 as compared to control.  This migratory effect could 
be inhibited with an anti-CXCR2 antibody.  Interestingly, these investigators also evaluated the 
influence of IL-8 on components of the basement membrane, and found that IL-8 caused a 
transient six-fold increase in adhesion to laminin by this prostate cancer cell line.  They 
hypothesized that the upregulation in laminin not only facilitated migration in this cell line but 
also provided a key insight into initiating invasion through the basement membrane (69). 
IL-8 signaling and cancer cell interaction with components of the basement has been 
focused on in other types of cancer cell lines, as well.  Chronic lymphocytic leukemia (CLL) 
cells appear to be dependent on binding of hyaluronan for movement through the lymphatic 
system.  However, the presence of surface hyaluronan, alone, was not enough to induce CLL 
migration in vitro.  The addition of exogenous IL-8 induce motility in these cells, but the 
motogenic effects could be ablated with addition of either anti-IL-8 antibodies or hyaluronidase 
(70).  IL-8 has been shown to induce migration in gastric cancer cell lines, as well (71–74).    Ju 
and colleagues found that the IL-8 induced a dose dependent migratory effect in a gastric cancer 
cell line, and they also found a dose-dependent upregulation of E-cadherin and intercellular 
adhesion molecule-1 (ICAM-1), two basement membrane proteins that are integral for cell 
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migration and adhesion within the vasculature under normal physiologic conditions (74).  IL-8-
induced upregulation of ICAM-1, in addition to vascular adhesion molecule-1 (VCAM-1) and 
cluster of differentiation 44 (CD44), was recapitulated in a later study as well.  These 
investigators found that the IL-8’s migratory effects and induction of adhesion molecules were 
mediated through NF-κB and Akt signaling (73).  Recent research in a gastric cancer cell line has 
shown that IL-8 interacts with metadherin, a protein coded by a well-described oncogene 
(MTDH gene).  Metadherin appears to upregulate the expression of IL-8, and when the IL-
8/metadherin interaction was attenuated in vitro, cell migration and invasion could be inhibited 
(71). 
An autocrine or paracrine mechanism for the motogenic effects of IL-8 in breast cancer 
has been described.  Breast cancer cells co-cultured with mesenchymal stem cells can be induced 
to produce IL-8, among other cytokines.  Inhibition of migration was achieved with IL-8 
neutralization (75).  Ataxia-telangectasia mutated (ATM) protein kinase, an important protein 
classically thought to be tumor suppressive in nature given its capacity to induce DNA repair 
pathways, has been implicated in inducing migration in breast cancer cell lines by regulating IL-
8 gene expression.  ATM depletion reduced IL-8 gene promoter activity and gene expression.  
Furthermore, it was demonstrated that depleting ATM diminished NF-κB binding to the IL-8 
gene promoter, which was hypothesized to be the likely cause of overall reduced gene expression 
(76).  In a triple negative breast cancer (TNBC) cell line, experimental constitutive activation of 
MEK resulted in the upregulation of IL-8 by this cell line.  A MEK inhibitor not only attenuated 
IL-8 gene expression and protein production, but also impeded cell migration (77).  Recently, 
leptin, a hormone released from adipose tissue that influences cellular metabolism, has been 
found to cause an up-regulation in IL-8 production in M2 macrophages, and breast cancer cell 
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lines co-cultured with these leptin-stimulated macrophages exhibited improved migration and 
invasion when compared with breast cancer cells alone (78).  This research reinforces the salient 
point that the tumor microenvironment likely influences the cancer phenotype just as much as the 
cancer cells influences their environment. 
Until very recently, there has been little published literature that specifically characterizes 
the motogenic effect of IL-8 in an osteosarcoma (OS) cell line.  A recent study did show that 
galectin-3, a protein that is thought to promote malignant transformation and metastasis 
primarily through β-catenin/Wnt signaling, can regulate the expression of IL-8 in a human OS 
cell line.  Inhibition of galectin-3, inhibited IL-8 among other cytokines, and attenuated cellular 
migration which was hypothesized to be largely mediated through FAK, Akt, and/or β-catenin 
(79).  Even more recently, Jiang and others proved that addition of IL-8 to cell culture enhanced 
migration and invasion of a human OS cell line.  These investigators also found that addition of 
exogenous IL-8 to cell culture resulted in significantly increased concentrations of 
phosphorylated PI3K and Akt, and they concluded that the PI3K/Akt signaling pathway was 
likely paramount to OS motogenesis (80). 
 
2.2.3 IL-8 and cell survival 
Resisting cell death is another hallmark of cancer that was identified in Hanahan and 
Weinberg’s seminal paper (7), and there is a wealth of evidence to support that IL-8 signaling 
promotes cell survival in both normal physiologic and neoplastic settings.  Not only does IL-8 
appear to serve as a potent chemoattractant for neutrophils, IL-8 appears to perpetuate the 
inflammatory response by allowing neutrophils to resist spontaneous apoptosis.  When 
investigating methods to attenuate inflammation in lower airway inflammatory disease, 
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investigators discovered that neutrophils cultured with exogenous IL-8 had a significantly lower 
rate of apoptosis than control settings.  Furthermore, with a selective CXCR2 antagonist, the pro-
survival effects of IL-8 on neutrophils were inhibited (81).  Because the inhibitory effect of the 
CXCR2 antagonist on survival was 5 times higher when cells were co-cultured with IL-8 as 
compared to when cells were co-cultured with a selective CXCR2 agonist, growth related 
oncogene-α (GRO-α), the investigators also hypothesized that IL-8 signaling through CXCR1 is 
likely involved in cellular resistance of apoptosis (81). 
The anti-apoptotic effects of IL-8 have also been demonstrated in HUVECs and HMECs.  
Similar to neutrophils, Li and others found that both endothelial cell lines exhibited significantly 
higher percentages of apoptotic cells in control conditions and in low concentrations of 
exogenous IL-8 (1 ng/ml) when compared to high concentrations of IL-8 (10 ng/ml).  
Furthermore, characterization of gene expression in the cells co-cultured with a high IL-8 
concentration showed significant up-regulation in the anti-apoptotic genes Bcl-2, Bcl-xl, and 
Bxl-xs (41).  These investigators hypothesized that IL-8-mediated endothelial cell resistance to 
apoptosis is an important component in the promotion of angio- and vasculogenesis in an 
inflammatory setting and in a tumor microenvironment. 
 
2.2.3.1 IL-8 and cell survival in neoplasia 
There is also a wealth of literature to support IL-8’s anti-apoptotic properties in cancer 
cells.  This chemokine’s anti-apoptotic effects and its ability to endow cancer cells has been most 
extensively described in prostate cancer (6,8,82–85).  After demonstrating that a hypoxic 
environment could upregulate IL-8 and its cognate receptors in prostate cancer cells through 
overexpression of the transcription factors hypoxia-inducible factor-1α (HIF-1α) and NF-κB, 
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Maxwell and others showed that IL-8 signaling enhanced chemoresistance to etoposide (82).  
NF-κB-upregulation of Bcl-2 and survivin was theorized to be the mechanism of IL-8-induced 
chemoresistance in androgen-independent prostate cancer cell lines to oxaliplatin, as IL-8 
signaling blockade using a CXCR2 antagonist reversed NF-κB,Bcl-2, and survivin upregulation 
and enhanced cell killing with oxaliplatin (83).  CXCR2 antagonism also proved useful at 
chemo-sensitizing androgen-independent prostate cancer cells to two antimetabolite 
chemotherapeutics (85).  In addition to NF-κB upregulation, IL-8 signaling may allow for 
evasion of apoptosis in prostate cancer cell lines through the upregulation of cyclin D.  Cyclin D 
is important in regulating cell cycle progression from G1 to S phase, and over-expression inhibits 
appropriate apoptosis and allows for cells with aberrant genetic make-up to replicate (8).  Similar 
studies using cell lines and xenografted tumors in mice provided convincing evidence that IL-8 
signaling also endows colorectal cancer with chemoresistance to oxaliplatin in vitro and in vivo 
(86–88). 
 In addition to prostate and colorectal cancer, IL-8-induced chemoresistance secondary to 
downregulation of apoptosis is well described in ovarian cancer.  The addition of exogenous IL-8 
to cell culture, as well as transfection to create cells that over-express IL-8, endowed ovarian 
cancer cells with chemoresistance to both cisplatin and paclitaxel as compared to a control cell 
culture setting (10).  IL-8 knockdown and IL-8 receptor antagonism significantly enhanced 
cisplatin cytotoxicity in multiple platinum resistant ovarian cancer cell lines (89).  Mechanisms 
underlying cell survival in these studies not only included resistance to apoptosis through 
upregulation of Bcl-2, increased inhibitory phosphorylation of Bad (pro-apoptotic protein), and 




 The effects of IL-8 signaling on survival and chemosensitivity has been examined in 
osteosarcoma (OS), but to the author’s knowledge, only one study has specifically investigated 
this topic in OS to date (90).  In this study, CXCR1 knockout technology was used to show that 
inhibition of signaling through CXCR1 improved cytotoxicity of cisplatin to OS cell lines in 
vitro.  Furthermore, after systemic treatment with cisplatin, orthotopic CXCR1-knockdown OS 
tumors in mice were significantly smaller than those tumors formed from cell lines in which 
CXCR1 signaling was intact.  The investigators hypothesized that signaling through the Akt 
pathway was largely responsible for the chemoresistant phenotype as CXCR1 knockout was 
proven to significantly reduce phosphorylated Akt in vitro (90). 
 
2.2.4 IL-8 and angiogenesis 
 Since the time of its description, IL-8 has been implicated in normal angiogenesis, and it 
has since been described as an important contributor to tumor angiogenesis in a variety of 
cancers.  Shortly after its discovery, Koch and others were the first to describe the potent 
chemotactic effects of IL-8 on HUVECs (56), and multiple groups using angiogenesis assays in 
rat corneal tissues and sponge models corroborated IL-8’s proangiogenic effects in vivo 
(56,91,92).  IL-8 initiates angiogenic pathways in endothelial cells by binding CXCR1 and 
CXCR2 on the cell surface.  It has been hypothesized that the glutamine-leucine-arginine (ELR) 
motif located on the amino terminus and its binding to cell surface receptors is essential for IL-
8’s, as well as other CXC chemokines, angiogenic properties (65,67).  Specifically, ELR motif 
binding to CXCR2 is theorized to be responsible for initiation of an angiogenic pathway as 
neutralizing antibodies to CXCR2 have been shown to mitigate endothelial cell migration in 
vitro and prevent blood vessel formation in vivo in corneal angiogenesis assays (94).  Further 
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support for the ELR motif’s critical role in IL-8-induced angiogenesis is supported by the finding 
that chemokines lacking the ELR motif can prevent angiogenesis, even in the presence of pro-
angiogenic chemokines and growth factors, like fibroblast growth factor (FGF) and vascular 
endothelial growth factor (VEGF) (91,93).  In addition to the ELR motif, IL-8’s proangiogenic 
effects were further characterized in the aforementioned work by Li and others that proved that 
IL-8 promotes angiogenesis by inhibiting apoptosis in endothelial cells by upregulating anti-
apoptotic genes (41). 
 Mechanistically, IL-8 induced angiogenesis is thought to be dependent on the resultant 
upregulation of transcription factor NF-κB, which has been shown to directly upregulate VEGFR 
and one of its cognate receptors, VEGFR2, in endothelial cells (95).  Autocrine and paracrine 
signaling through VEGF and VEGFR2 initiates and potentiates angio- and vasculogenesis.  
Moreover, IL-8 release from neutrophils has been shown to upregulate IL-8 expression by 
endothelial cells, which creates an autocrine positive feedback cycle, further promoting 
angiogenesis (96). 
 
2.2.4.1 IL-8 and angiogenesis and neoplasia  
IL-8’s role in tumor angiogenesis has been heavily investigated and is well-substantiated.  
IL-8 investigation in a variety of breast cancer cell lines not only revealed that IL-8 was 
correlated with increased angiogenesis, but also increased invasiveness.  Neutralizing antibodies 
against IL-8 mitigated angiogenesis in this study (97) and in another in which breast cancer cells 
were co-cultured with HUVECs (11).  In another study, IL-8 mediated angiogenesis in a breast 
cancer cell line, as well as a colorectal cancer cell line, was shown to be stimulated by lactate 
influx into the neoplastic cells themselves (98).  IL-8, among other angiogenic factors, was also 
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found to be upregulated in the presence of progesterone, estrogen, and epidermal growth factor 
(EGF) in the MCF-7 breast cancer cell line (99). 
 In addition to breast cancer, IL-8 appears to endow enhanced angiogenesis in prostate 
(100,101), colorectal (86,102), lung (103,104), melanoma (105), and pancreatic cancer (106) cell 
lines, to name a few.  Various prostate cancer cell lines transfected with IL-8 exhibited a 3 to 5-
fold increase in VEGF and matrix metalloproteinases, as compared to controls, and when 
transfected cell lines were injected into mice, xenografted tumors had significantly increased 
microvessel density (MVD) (100).  Additionally, research using low and high IL-8 producing 
human prostate cancer cell lines orthotopically implanted into mice prostates showed that tumors 
caused by high IL-8-producing cell lines were significantly more vascularized and more 
metastatic than tumors formed from low IL-8-prodcuing cell lines (101).  Similar to studies with 
prostate cancer cell lines, colon cancer xenografted tumors in mice were larger and had increased 
tumor MVD if IL-8 was overexpressed, as well (86).  Interestingly, IL-8 has been shown to 
potentiate angiogenesis in colon cancer cell lines by upregulating NF-κB and VEGF even when 
HIF-1α is knocked out (102), which highlights the multifaceted and redundant signaling cascades 
used by cancer cells and why targeting single pathways in cancer typically leads to a modest 
biologic effect.  
 In NSCLC cell lines, the use of a selective CXCR1 and CXCR2 antagonist significantly 
inhibited angiogenesis when compared to controls.  It was found that IL-8 signaling blockade 
was associated with reduced expression of both VEGF and NF-κB in vitro and with significantly 
reduced intratumoral MVD in orthotopic tumors in vivo  (107).  Additionally, an 
immunhistochemical study examining IL-8 expression in tumors from people with NSCLC 
showed that MVD was significantly higher in IL-8 positive tumors as compared to IL-8 negative 
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tumors (104).  Similar to the work in NSCLC, small molecule antagonism of IL-8’s cognate 
receptors also resulted in decreased MVD in orthotopic tumors produced by a melanoma cell line 
(105).  
 There is limited data concerning the effects of IL-8 on angiogenesis in osteosarcoma.  
Tan and others have shown that both IL-8 and VEGF were upregulated in an osteosarcoma cell 
line when co-cultured with fibroblasts or HUVECs in a three-dimensional (3D) culture setting.  
Furthermore, this group was able to show that IL-8 was primarily responsible for endothelial cell 
migration in this 3D co-culture setting.  It was shown that an IL-8 neutralizing antibody 
significantly halt HUVEC migration, whereas a VEGF neutralizing antibody had little effect on 
migration (108).  Ultimately, these investigators concluded that IL-8 might serve as a superior 
druggable target for anti-angiogenic therapy than commonly investigated and used anti-VEGF 
therapies (bevacizumab). 
 
2.3 IL-8 in clinical oncology 
 Understanding the role of IL-8, its associated signaling pathways, and the implications 
that this signaling has on cancer cells in the laboratory setting has allowed IL-8 to become a 
potential biomarker and druggable target in a clinical oncologic setting in people.  Given that IL-
8 signaling seems to endow cancer cells with a potentially more aggressive phenotype, it is not 
surprising that IL-8 has been frequently implicated as a negative prognostic biomarker for a 





2.3.1 IL-8 in breast cancer 
 Elevated serum IL-8 in patients with breast cancer has been recognized multiple times 
over to be a negative prognostic indicator for overall disease outcome (12,109–112).  Benoy and 
others were the first to show that not only was serum IL-8 significantly elevated in patients with 
breast cancer as compared to healthy controls, but also that IL-8 was correlated with increased 
tumor burden and the presence of metastasis (lymph node, liver, or bone marrow).  Furthermore, 
it was proven that elevated serum IL-8 was a negative prognostic factor for post-relapse survival 
(109).  These findings were substantiated in a later study in which elevated IL-8 was 
significantly associated with lymph node metastasis and significantly shorter overall median 
survival time in patients with breast cancer (110).  Using immunohistochemistry, it was shown 
that not only was IL-8 expression significantly higher in malignant mammary tumors than in 
normal breast tissue or benign mammary tumors, but also that IL-8 expression was significantly 
higher in those patients with metastatic breast cancer when compared to those patients without 
metastasis.  Not surprisingly, high IL-8 was also associated with a significantly worse overall 
median survival time (12).  
 In addition to overall disease outcome, IL-8 expression in breast cancer has also been 
consistently correlated with breast cancer receptor expression.  High IL-8 expression has been 
consistently correlated with negative estrogen receptor (ER) expression and positive human 
epidermal growth factor receptor 2 (HER2) expression (110–114), which are both generally 
associated with a poorer response to therapy and outcome when compared to ER-positive and 
HER2-negative breast cancers.  There is also evidence to suggest that IL-8 expression in vivo 
could be grooming the microenvironment to facilitate metastasis.  Upregulation of MMP-9, 
which is theorized to be important for invasion of solid tumors into surrounding tissues and 
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blood vessels, and TNF-α, which is cytokine that perpetuates a pro-inflammatory peri-tumoral 
microenvironment, are positively correlated with IL-8 expression in breast cancer (111,112). 
 
2.3.2 IL-8 in non-small cell lung cancer 
Non-small cell lung carcinoma (NSCLC) is another common and devastating malignancy 
in which IL-8 has been shown to correspond with a more aggressive disease phenotype.  One of 
the initial seminal investigations evaluated messenger RNA (mRNA) expression in primary 
tumors from patients with NSCLC.  This study showed that increased IL-8 mRNA expression 
was positively correlated with aberrant p53 mRNA expression, VEGF mRNA expression, and 
overall tumor MVD.  Furthermore, it was those patients with tumors with high IL-8 expression 
that had a significantly shorter survival than those patients with low IL-8 expression (13).  In a 
later, similar study, high IL-8 expression in NSCLC tumors was correlated with high expression 
of the mutated oncogene, k-Ras.  Additionally, high IL-8 expression was associated with a 
significantly shorter disease free survival and overall survival (115).  Serum IL-8 concentrations 
have been shown to drop rapidly following surgical resection of tumors, and preoperative serum 
IL-8 concentrations are correlated with higher tumor burden and stage (116).  In a small clinical 
study evaluating the efficacy of monoclonal antibodies to programmed cell death receptor 1 (PD-
1) and its association with serum IL-8, it was shown that NSCLC patients treated with these 
immunotherapeutics that had a significant drop in IL-8 concentrations from baseline had 
significantly longer overall survival as compared to those patients who had no change or an 
increase in serum IL-8 concentrations (117).   Interestingly, in addition to being potentially a 
negative prognostic factor, high serum IL-8 was shown to be a risk factor for the eventual 
development of NSCLC, especially in smokers (118). 
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2.3.3 IL-8 in miscellaneous solid tumors 
 Other solid tumors in which serum IL-8 has been shown to potentially provide prognostic 
information about patient outcome include prostate cancer, colorectal cancer, hepatocellular 
carcinoma, renal cell carcinoma, ovarian cancer, pancreatic cancer, oral squamous cell 
carcinoma, and melanoma.  In regards to prostate cancer, serum IL-8 was significantly higher in 
those patients with prostatic carcinoma as compared to those patients with benign prostatic 
hyperplasia (14) and high intratumoral IL-8 mRNA expression was positively correlated with an 
advanced histologic Gleason score and advanced clinical stage of disease (119).  A meta-analysis 
evaluating the correlation between IL-8 and overall outcome of patients with colorectal cancer, 
which included 18 different studies, found that high IL-8 was significantly associated with 
advanced cancer stage, lymphatic metastasis, hepatic metastasis, and poorer overall survival 
(120).  Another meta-analysis evaluating cytokine expression in pancreatic ductal 
adenocarcinoma identified 6 studies documenting significantly higher IL-8 expression in patients 
with cancer when compared to patients with other pancreatic diseases or healthy controls.  
Furthermore, when used in combination with the well-substantiated pancreatic cancer biomarker, 
CA 19-9, the combination of the two improved the ability to differentiate between patients with 
pancreatic cancer and healthy controls when compared to CA 19-9 alone (121). 
Similar to breast, NSCLC, and colorectal cancer, high serum IL-8 was also significantly 
associated with increased tumor burden, advanced stage, and poorer median survival times in 
hepatocellular carcinoma, renal cell carcinoma, and melanoma (15,116,117).  Interestingly, not 
only have serum IL-8 concentrations in patients with oral squamous cell carcinoma (OSCC) been 
shown to be significantly higher than in healthy controls, but also salivary IL-8 concentrations 
have been shown to be consistently higher in OSCC patients (16).  In hematopoietic tumors, IL-8 
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has not been shown to be as consistently related to an aggressive cancer phenotype when 
compared to solid tumors.  No significant difference in serum IL-8 concentrations was noted 
between control patients and patients with non-Hodgkin’s lymphoma (122).  Although IL-8 is 
capable of inducing proliferation and migration in multiple myeloma cells from patients (123), 
there is no published literature to substantiate this chemokine’s role as a biomarker in multiple 
myeloma.   
 
2.3.4 IL-8 in osteosarcoma 
High expression of IL-8 and IL-8 serum concentrations have also been shown to have 
prognostic importance in patients with OS.  In a cross-species genomic investigation, it was 
found that humans with tumors that had high levels of IL-8 expression had a significantly poorer 
overall survival time as compared to those patients with OS that had tumors with low IL-8 
expression (22).  A later study examining serum cytokines in patients with osteosarcoma were 
not only significantly more elevated in patients with OS as compared to controls, but also that 
high serum IL-8 was significantly correlated with tumor size at the time of presentation (124).  
Serum IL-8 was also found to be significantly higher in patients with OS as compared to controls 
in two other studies, but no information regarding patient characteristics or patient outcome was 
provided in these studies (80,125). 
 
2.4 Targeting IL-8 and the IL-8 signaling axis in clinical oncology 
 Given that IL-8 is clearly involved in the progression of some cancers by promoting a 
more aggressive cancer phenotype, targeting this chemokine, directly, and/or its signaling axis 
could result in enhanced anti-cancer, and principally anti-metastatic, treatment efficacy.  A 
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wealth of literature chronicling targeting of downstream effectors of the IL-8 signaling axis, like 
NFκB, PI3K/Akt, and MAPK, is published and discussion of these strategies is beyond the scope 
of this review.  However, little work in directly targeting IL-8 and signaling through its cognate 
receptors has been carried out in a clinical oncology setting. 
 
2.4.1 IL-8 receptor inhibition 
 Reparixin is a non-competitive, allosteric inhibitor of IL-8’s cognate receptors, CXCR1 
and CXCR2.  However, this inhibitor has been shown to bind much more selectively to CXCR1 
(6).  Preliminary in vivo work with Reparixin showed that treatment, in combination with a 
taxane chemotherapeutic, was effective at reducing overall tumor burden, as well as the cancer 
stem cell population, in a breast cancer xenograft model (126).  Based on these findings, a phase 
I study with Reparixin and paclitaxel with HER2-negative, metastatic breast cancer was 
performed and showed that this combination was safe and tolerable in patients (127).  A phase II 
study with the aforementioned combination is ongoing. 
 
2.4.2 IL-8 neutralization with monoclonal antibodies 
 Monoclonal antibodies against IL-8 have also been developed, and their use in preclinical 
work did show promise.  One melanoma xenograft study showed that the use of an IL-8 
monoclonal antibody inhibited MMP-2 production, induced apoptosis in tumor cells, and 
significantly reduced tumor growth (128).  A phase I clinical trial at the National Cancer institute 
evaluating the HuMax-IL8 monoclonal antibody in patients with metastatic solid tumors has 
been completed; however, results of this study have yet to be published.  This clinical trial is 
unique, as research with other neutralizing IL-8 antibodies have not been carried forward to a 
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clinical oncology setting to date.  The reasoning behind this is likely because chemokine 
neutralizing antibodies are hypothesized to not be especially effective as there is often redundant 
signaling through chemokine receptors initiated by chemokines in the microenvironment other 
than the one targeted (1,6,17).  Monoclonal antibodies against chemokine receptors are likely to 
have a more profound biologic effect, so more research into the development of these molecule 
is needed. 
 
2.5 IL-8 and veterinary oncology 
 There is a scarcity of information regarding IL-8 and its role in tumorigenesis, disease 
progression, and outcome in veterinary oncology.  Gelaleti and others were the first to 
investigate IL-8 as potential biomarker for canine mammary tumor.  In this study characterizing 
serum IL-8 in 30 dogs with mammary carcinoma, it was shown that not only was IL-8 
significantly higher in tumor-bearing dogs as compared to controls, but also that high serum IL-8 
was positively and significantly correlated with increased tumor burden (i.e. multiple tumors), 
tumor recurrence, lymph node metastasis, and increased risk of death due to disease (129).  
 The effects of IL-8 in canine hemangiosarcoma (cHSA) in vitro and in vivo in a mouse 
model have been investigated recently.  Although it was shown that various cHSA cell lines 
expressed IL-8 on a gene and protein level, no changes in proliferation or survival were realized 
when either exogenous IL-8 or a neutralizing monoclonal antibody to IL-8 was added to the 
cHSA cell lines.  However, interestingly, use of the IL-8 monoclonal antibody successfully 
inhibited xenograft tumor formation and growth.  The investigators hypothesized that IL-8 
signaling likely contributed to fostering an inflammatory microenvironment that perpetuated 
tumor growth in vivo.  Genomic analysis supported this hypothesis, as genes involved in 
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inflammation and coagulation were upregulated in cHSA cell lines that were high expressers of 
IL-8 compared to low expressers (130).  Finally in another recent study evaluating the oncogenic 
potential of the ΔNp63, an antagonistic, oncogenic, structural analog of a tumor suppressor gene 
in the p53 family, in canine osteosarcoma (OS), it was concluded that IL-8 secretion was 
stimulated by ΔNp63 and that subsequent IL-8 signaling through VEGF A was essential for 
angiogenesis in vitro (131). 
 
2.6 IL-8 in comparative oncology 
 A pivotal study from Paoloni and others at the National Cancer Institute clearly 
established the presence of IL-8 expression in OS in both people and dogs and suggested that the 
IL-8 signaling pathway could serve as a potential druggable target to better the outcome for 
patients of both species with this aggressive malignancy.  In this study, the investigators 
eloquently showed that gene expression signatures between canine and human tumors were 
highly similar and could not be distinguished from one another on cluster analysis.  Furthermore, 
they went on to identify a few genes that were uniformly overexpressed in canine tumors.  IL-8, 
among others, was identified as one of these “dog-like” genes.  Because OS is a more aggressive 
malignancy in dogs than in people, it was hypothesized that those human patients whose tumors 
had increased expression of those “dog-like” genes consistently overexpressed in canine OS 
would have a worse overall outcome.  Interestingly, it was discovered that, indeed, high IL-8 
expression was associated with a poorer outcome in human patients with OS (22).  This 
comparative genomic study established the role of the dog as an important model of OS in 
people.  Furthermore, it established the need to further investigate IL-8, its associated signaling 
pathways, and its potential to be targeted in canine OS. 
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2.7 Canine osteosarcoma 
 Canine osteosarcoma (OS) is the most common primary bone tumor diagnosed in dogs.  
OS more commonly affects the metaphyseal region of the appendicular skeleton, with only about 
25% of cases affecting the axial skeleton (19,20).  Forelimbs are affected about twice as 
commonly as the hind limbs, and the distal radius and proximal humerus are consistently 
identified as the most common locations for the disease.  Appendicular OS typically affects older 
large and giant breed dogs; however, a bimodal disease distribution has been described with a 
peak in OS incidence around 2 years of age (19,21,132).  OS is a highly locally invasive disease, 
and tumor disruption of the periosteum causes severe bone pain in patients.  OS is also highly 
metastatic.  Although only 10-15% will have visible evidence of pulmonary metastatic disease at 
the time of diagnosis, more than 90% of patients will eventually succumb to pulmonary 
metastatic disease, which is secondary to occult micrometastatic disease at the time of diagnosis 
(18).  Other described, but less common, sites of metastasis include other bones and viscera 
(133,134). 
 Veterinary patients with OS commonly present for evaluation of a chronic, progressive 
lameness.  Sometimes a visible, firm swelling affecting a long bone can be palpated on physical 
exam.  Radiographs of the affected limb often reveals an aggressive bone lesion, characterized 
by areas of both osteoblastic production and osteolysis.  Although the combination of the 
patient’s signalment and the radiographic appearance of the lesion, alone, is often enough to be 
highly suggestive of OS, a definitive diagnosis can typically be obtained with a fine needle 
aspirate or a core biopsy of the lesion.  A recent study comparing cytology and biopsy for 
primary malignant bone tumors showed that the diagnostic accuracy of cytology and biopsy were 
83% and 82.1%, respectively (135).  The use of an alkaline phosphatase stain is an invaluable 
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tool for cytopathology that can be used to differentiate OS from other sarcomas (136,137).  After 
obtaining a diagnosis and prior to any definitive therapy, thorough staging with a blood cell 
count, serum chemistry panel, urinalysis, thoracic and abdominal imaging, and bone scintigraphy 
should be considered. 
 
2.7.1 Canine osteosarcoma treatments 
 The most effective therapies for OS are directed at eliminating tumor-related bone pain 
and slowing down the rate of metastatic disease progression.  An amputation surgery of the 
affected limbs followed with systemic chemotherapy is consistently reported to result in the 
longest survival times in veterinary patients with OS with median survival times ranging from 10 
months to nearly a year (138–141).  A variety of chemotherapy protocols have been investigated 
for OS, and platinum-based or doxorubicin-based protocols seem to be the most effective (141).  
Treatment with conventional chemotherapy with concurrent or subsequent treatment with 
metronomic chemotherapy and/or the small molecule inhibitor toceranib phosphate (Palladia®) 
has not resulted in improved outcomes when compared to those patients treated with 
conventional therapy alone (142–145). 
 In patients not able to undergo amputation surgery due to pre-existing orthopedic disease 
or due to owner preference, limb-sparing therapies should be considered to control bone pain.  
Limb sparing surgery techniques involving resection of affected bone and replacement with bone 
allograft or metal endoprosthesis implants are well described.  However, these surgeries are 
typically reserved for patients with minimally-invasive, distal radial or ulnar disease and can be 
fraught with complications like infection or implant failure (146,147).   
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External beam radiation therapy is another limb-sparing treatment modality that can be 
considered for veterinary patients with OS.  Stereotactic radiation therapy, which employs 
image-guidance to deliver high doses of highly conformal radiation directly to the tumor while 
sparing adjacent normal tissues, with adjuvant chemotherapy has recently been described as an 
effective therapy for appendicular OS in dogs that results is favorable pain control and median 
survival times similar to outcomes with standard therapy (148–151).  Palliative radiation therapy 
is another well-described treatment modality for canine OS, and although approximately 90% of 
dogs will have clinical improvement, pain control with palliative protocols does not appear as 
durable when compared to stereotactic therapy (148,152–157).  
Multimodal analgesic protocols with bisphosphonates, non-steroidal anti-inflammatory 
drugs, opioids, and/or neuropathic pain inhibitors (gabapentin, amantadine) should be considered 
in any case in which the primary tumor cannot be excised.  Although combination therapy, 
especially if bisphosphonates are included, does improve pain control for the majority of OS 
patients, the response with medical management, alone, is short-lived with approximate median 
survival times reported in 3-4 month range (132,158–160). 




MATERIALS AND METHODS 
3.1 Cell lines 
Six canine OS cell lines were used in this study: Abrams, Gracie, K003, McKinley, 
Moresco, and Vogel.  A canine aortic endothelial cell line (CnAoEC) was also used.  All cell 
lines were graciously provided by Professor Doug Thamm (Flint Animal Cancer Center, 
Colorado State University).  OS Cell cultures were maintained in a Dulbecco’s Modified Eagle’s 
Medium with glucose (4.5 g/L), glutamine, and sodium pyruvate (DMEM), which also contained 
10% fetal bovine serum (FBS), penicillin (100 IU/ml), and streptomycin (100 IU/ml).  CnAoEC 
were maintained in a commercially available endothelial cell media.  Cultures were housed in a 
humidified incubator at 37°C with 5% carbon dioxide.  Cells were passaged as needed, prior to 
formation of a confluent monolayer. 
For preparation for freezing, cells were trypsinized and then centrifuged (1500 rpm for 5 
min at 5°C).  Supernatant was discarded the cell pellet was resuspended in a freezing media 
containing 50% DMEM, 40% FBS, and 10% dimethyl sulfoxide (DMSO).  Aliquots of cells and 
freezing media were placed in cryogenic tubes and frozen in a Mr. Frosty ™ freezing container 
at -80°C. 
 
3.2 Reagents and antibodies 
Forward and reverse primers for CXCR1 (CGCTCCTGAAGGAGGTCAAC and 
AGCCCATAGCAGAACAGCAT respectively), forward and reverse primers for CXCR2 
(CGCTCCTGAAGGAAGTCAAC and AGCCCATAGCAGAACAGCAT, respectively), and 
forward and reverse primers for GAPDH (GGAAATCCCATCACCATCTTCCA and 
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CATCACGCCACAGTTTCCCGGAG, respectively) were purchased from Integrated DNA 
Technologies (Coralville, IA).  Anti- IL-8 (mouse monoclonal [8M6]; ab34100), anti-CXCR1 
(mouse monoclonal [501]; ab 60254), anti-CXCR2 (rabbit polyclonal; ab14935), and anti-β-actin 
antibody (mouse monoclonal; AC-15; ab6276) were purchased from Abcam Biochemicals 
(Cambridge, MA).  The non-selective CXCR1 and CXCR2 inhibitor, Reparixin (αR-methyl-4-
[2-methylpropyl]-N-[methylsulfonyl]-benzenacetamide), was purchased from Cayman Chemical 
(Ann Arbor, MI). 
  
3.3 Reverse transcriptase polymerase chain reaction 
Cell pellets from canine osteosarcoma cell lines Gracie, McKinley, Moresco, and Vogel 
and from the canine aortic endothelial cell line (CnAoEC) were collected via trypsinization and 
centrifugation.  After centrifugation, the trypsyin/cell media supernatant was discarded and cell 
pellets were homogenized with PBS.  Repeated centrifugation followed by removal of PBS 
supernatant was performed before RNA isolation from cell pellets.  The RNAeasy extraction kit 
(RNeasy mini kit, Qiagen, Valencia) was used to isolate RNA from cell pellets.  
Spectrophotometry (NanoDrop ®) was performed to evaluate RNA concentration within 
samples.  RNA was reverse transcribed into cDNA(SuperScript First-Strand cDNA Synthesis 
Kit, Invitrogen, Carlsbad, CA).  Using a thermal cycler, amplification of cDNA was performed, 
using primers for human CXCR1 and human CXCR2 (Integrated DNA Technologies, Coralville, 
IA).  Gel electrophoresis of amplified DNA sequences was performed on an agarose gel 
containing ethidium bromide.  Amplified sequences were visualized on the gel using Image Lab 




3.4 Protein collection 
Confluent, or nearly confluent, cell culture plates were used for protein collection.  First, 
cells were trypsinized and then centrifuged (1500 rpm for 5 min at 5°C).  Supernatant was 
discarded the cell pellet was resuspended in sterile phosphate-buffered saline (PBS).  The 
resuspended cells were again centrifuged at an increased rotational speed (10000 rpm for 5 min 
at 20°C).  The PBS supernatant was discarded, and if not used for immediate protein extraction 
and collection, the cell pellet was stored indefinitely at -80°C. 
For protein collection, cell pellets were resuspended in 100 µL of a stock solution 
containing 1 mL of Mammalian Protein Extraction Reagent (Pierce, Rockford, IL) mixed with 
10 µL of a protease inhibitor solution (Pierce, Rockford, IL).  The homogenized mixture was 
agitated on a mechanical shaker for 15 minutes.  Afterwards, the mixture was again centrifuged 
at 10000 rpm for 5 min at 20°C.  The supernatant was collected and protein concentration was 
determined using a Bicinchoninic Acid Protein Assay Kit (Pierce, Rockford, IL).  After protein 
quantification was performed, samples were generally used immediately, but when immediate 
use was not possible, samples were maintained at -20°C. 
 
3.5 Western blotting 
For each Western blot performed, 50 µg of protein was loaded on a 12 % polyacrylamide 
gel.  Gel electorphoresis (80 V for 1 hr) was performed, and samples were then 
electrophoretically transferred (55 V for 45 min) to a nitrocellulose membrane.  The 
nitrocellulose membrane was then blocked with Tris-buffered saline with Tween 20 (TBST) with 
5% milk for 1 hr at 20°C.  Western blot was performed using anti-human IL-8, CXCR1, and 
CXCR2 antibodies.  All antibodies were used at a concentration of 1:1000 in TBST with 5 % 
33 
 
milk.  Membranes were exposed to primary antibodies for 12 hr at 4°C and then washed 4 times 
with TBST.    Membranes were then incubated for 1 hr at 20°C with the appropriate secondary 
antibodies at a concentration of 1:5000 in 5% milk.  After incubation, membranes were washed 
again 4 times with TBST and then developed immediately using ChemiDoc XRS+ molecular 
imager system (Bio-Rad, Hercules, CA).   β-actin was used as a loading control for all Western 
blot analyses.  Membranes were incubated for 30 min at 20°C with anti-human β-actin antibody 
at a concentration of 1:5000 in 5% milk.  Image Lab software (Bio-Rad, Hercules, CA) was used 
for band analysis in Western blotting. 
 
3.6 In-vitro IL-8 ELISA 
The Gracie, McKinley, Moresco, and Vogel cell lines were used for ELISA.  Cell lines 
were plated in triplicate in the following serial dilutions: 100,000 cells per well, 50,000 cells per 
well, 25,000 cells per well, 12,500 cells per well, 6,250 cells per well, and 3,125 cells per well.  
Cells were initially plated in DMEM with 10% FBS at 37°C for 6 hours.  Complete media was 
then removed and replaced with DMEM supplemented with 1% FBS.  Cells were incubated at 
37°C for 24 hours.  After incubation, the supernatant was collected and transferred to a 96-well 
plate.  ELISA samples were stored at -80°C until ready for use.  The concentration of IL-8 was 
determined using a commercially available ELISA kit (Quantikine® Canine CXCL8/IL-8 
ELISA kit, R&D Systems, Minneapolis, MN).  
 
3.7 Cell proliferation assays 
 The Gracie and Moresco cell lines were used for cellular proliferation assays.  Cells were 
plated in a 96 well plate so that each well contained 3000 cells in 100 µL of DMEM with 10% 
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FBS.  The plate was incubated at 37°C for 12 hours to allow for cell adherence.  Experimental 
conditions were then applied.  Cell proliferation was measured with the use of a colorimetric 
proliferation assay (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, 
Madison, WI ).  Assays were performed in hexaplicate and in three separate experiments.  
 Proliferation assays with the addition of exogenous IL-8 were carried out first.  For this 
assay the following experimental conditions were evaluated:  10% media only and 10% media 
with IL-8 at 0.3 ng/ml, 1.0 ng/ml, 3.0 ng/ml, and 10.0 ng/ml.  Cell proliferation was measured 
with the use of a colorimetric proliferation assay at 72 hr (Cell Titer Blue assay). 
 Proliferation assays using potentially inhibitory compounds were carried out next.  
Proliferation assays with carboplatin were first evaluated.  The following experimental 
conditions were used for this assay:  10% media only, 10% media with carboplatin at 1 μM, 3 
μM, 10 μM, 30 μM, 100 μM, and 300 μM.  Cell Titer Blue assays were initially carried out at 24, 
48, and 72 hr, in initial pilot assays.  However, due to lack of cellular cytotoxicity at 24 and 48 hr 
in these pilot studies, only proliferation at 72 hr was assessed.   
Assays with Gracie and Moresco exposed to varying concentrations of Reparixin were 
then evaluated.  The following experimental conditions were used: 10% media only, 10% media 
with Reparixin at 3 nM, 10 nM, 30, nM, 100 nM, 300 nM, and 1000 nM.  Colorimetric 
proliferation assays were initially carried out at 24 and 72 hr. 
 Assays with the previously described doses of carboplatin in combination with a fixed 
dose of Reparixin were then investigated.  The Reparixin dose of 100 nM was chosen as it is the 
IC50 of CXCR2, which is approximately 10 times greater than the IC50 of CXCR1.  Therefore, at 
this Reparixin dose, IL-8 signaling through its cognate receptors should be effectively attenuated.  
Colorimetric proliferation assays were initially carried out at 24 and 72 hr. 
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 Finally, proliferation assays with an IL-8 monoclonal antibody (mAb) were performed in 
the Gracie and Moresco cell lines.  The following experimental conditions were investigated:  10 
% media only, 10 % media with IL-8 mAb at 0.3 μg/ml, 1.0 μg/ml, and 3 μg/ml.  Proliferation 
was assessed at 72 hr.  Assays with the previously described doses of carboplatin in combination 
with a fixed dose of the IL-8 mAb (0.3 μg/ml) were then assessed in the Moresco cell line, and a 
colorimetric proliferation assay was assessed at 72 hr.  The Gracie cell line was excluded from 
this assay due to its known extreme production of IL-8 and the sheer quantity of IL-8 mAb that 
would be necessary to potentially achieve neutralization. 
 
3.8 Scratch assay 
Cell migration was assessed using a scratch assay method that has previously been 
described by Liang and others (161).  The Gracie and Moresco cell lines were used for scratch 
assays.  Cells were plated in 6 well plates so that each well contained 100,000 cells in 3 mL of 
DMEM with 10% FBS.  The plate was incubated at 37°C until cells were confluent.  Using a 200 
µL pipette tip, an acellular linear area was created through the confluent cells in each plate.  
Media and non-adherent cells were then aspirated from the plates so that experimental conditions 
could be evaluated.  The following experimental conditions were used for scratch assay 
experiments: DMEM with 10% FBS only, DMEM with 10% FBS with 30 nm of Reparixin, 
DMEM with 10% FBS with 100 nm of Reparixin, and DMEM with 10% FBS with 300 nm of 
Reparixin.  Each experimental condition was performed in duplicate for each cell line.  Images 
of the acellular linear area were obtained at time 0, 24 hours, and 48 hours after the initial scratch 
using an inverted microscope (Nikon Eclipse TS100) with a mounted digital camera (SPOT 
Insight QE model #4.2, SPOT Imaging Solutions, Sterling Heights, MI).  For each cell line and 
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each experimental condition evaluation, 5 width measurements that were representative of the 
linear acellular area were taken and averaged.  Average widths were used for cell migration 
comparison at 24 hours and 48 hours.   Image J software (National Institute of Health, Bethesda, 
MD) was used for data analysis. 
Scratch assays with Gracie and Moresco exposed to varying concentrations of the IL-8 
mAb were also carried out.  The following experimental conditions were investigated: DMEM 
with 10% FBS only, DMEM with 10% FBS and 0.3 ng/ml, DMEM with 10% FBS and 1.0 
ng/ml, and DMEM with 10% FBS and 3.0 ng/ml.  Only the 24 hour time point was able to be 
assessed in these experiments.  Data collection and analysis for this experiment were identical to 
the aforementioned protocol. 
 
3.9 Statistical analysis 
 The distribution of the continuous variable data was evaluated using the Kolmogorov 
Smirnov test.  When less than 12 data points were present, indicating that results of normality 
tests would not be reliable, a non-normal distribution was assumed. Kruskal-Wallis with Dunn’s 
comparison was used when a non-normal distribution was noted which was not corrected with 
log transformation of data.  A Mann-Whitney U-test was used to compare differences in 
proliferation between cells treated with chemotherapy alone and those treated with an identical 
dose of chemotherapy in combination with an additional agent (Reparixin or an IL-8 mAb).  
Statistical analysis was carried out using a commercially available software program (GraphPad 






4.1 IL-8 and its cognate receptors are expressed in osteosarcoma cell lines 
 Transcription of genes for IL-8, CXCR1, and CXCR2 was identified in canine OS cell 
lines Abrams, Gracie, K003, McKinley, Moresco, and Vogel by qualitative PCR (Figure 4.1).  
Expression of the 50 kDa protein was detected in all experimental cell lines demonstrating IL-8 
expression (Figure 4.2).  The expression of 45 kDa proteins demonstrated CXCR1 and CXCR2 
expression in all OS cell lines (Figures 4.3 and 4.4, respectively).   
 
4.2  IL-8 is differentially secreted by OS cell lines in a cell density-dependent manner 
 Active secretion of IL-8 was demonstrated by titration studies in four canine OS cell lines 
(Figure 4.5). There was a marked, differential production in IL-8 across the OS cell lines. The 
Gracie cell line demonstrated the greatest IL-8 secretion, producing more than four log orders 
more IL-8 than the other comparatively low-producing cell lines (Figure 4.6).  Given that 
Mckinley and Vogel did not display robust growth in cell culture, subsequent proliferation assays 
were carried out with the Gracie and Moresco cell lines so as to highlight potential differences 
between a high and a low IL-8 producing cell line, respectively (Figure 4.7). 
 
4.3 Exogenous IL-8 causes increased proliferation in a low IL-8-producing OS cell line 
 Cell Titer Blue Assays were performed with varying concentrations of IL-8 in the Gracie 
and Moresco cell line.  Based on data from pilot studies (not shown), proliferation assays with 
exogenous IL-8 were not developed until 72 hr of incubation as no consistently repeatable trends 
in changes in proliferation were ever observed in the Gracie or Moresco cell lines at other time 
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points.  In the Gracie cell line, significant decreases in proliferation were noted between control 
conditions and the 3.0 ng/ml treatment group (p < 0.0001) and between control conditions and 
the 10 ng/ml treatment group (p < 0.05) (Figure 4.8, A).  In the Moresco cell line, significant 
increases in proliferation between control conditions and the 10 ng/ml treatment group (p , 0.02), 
between the 0.3 ng/ml and 10 ng/ml treatment groups (p < 0.05), and between the 1 and 10 ng/ml 
treatment groups (p < 0.0002) were noted (Figure 4.8, B). 
 
4.4 IL-8 receptor blockade has no effect on proliferation in OS cell lines 
 To determine if attenuation of IL-8 signaling affects OS cell proliferation, cell titer blue 
assays were performed with varying concentrations of Reparixin.  Again, proliferation assays 
were only developed at the 72 hr time point as no repeatable trends in proliferation could be 
observed at other evaluated time points (data from pilot studies at 24, 36, and 48 hours is not 
shown).  The addition of Reparixin, alone, at varying concentrations did not cause a significant 
change in proliferation in the Gracie or Moresco cell lines at any of the doses examined (Figure 
4.9, A and B). 
 
4.5 IL-8 neutralization does not have an inhibitory effect on proliferation in OS cell lines 
 Cell titer blue assays were again performed with varying concentrations of an IL-8 
monoclonal antibody (mAb) in both the Gracie and Moresco cell lines.  At 72 hr in the Gracie 
cell line, there was a significant increase in proliferation between the control and the 1 μg/ml 
treatment groups (p < 0.0001) and between the control and 3 μg/ml treatment groups (p < 0.001) 
(Figure 4.10, A).  At 72 hr in the Moresco cell line, no significant differences in proliferation 
were observed at any of the IL-8 mAb concentrations evaluated (Figure 4.10, B). 
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4.6 IL-8 receptor blockade attenuates migration in a low IL-8-producing OS cell line 
 To determine whether or not manipulation of the IL-8 signaling axis affected migration in 
OC cells, scratch assays with varying concentrations of Reparixin were performed.  In the Gracie 
cell line after 24 hr of incubation with Reparixin, there was a significant increase in the percent 
of the acellular gap remaining between the control treatment and the 30 nM treatment groups (p 
< 0.05).  After 48 hr of incubation with Reparixin, significant decreases in the percent of the 
acellular gap remaining were observed between the control and the 100 nM treatment groups (p , 
0.001), between the control and the 300 nM treatment groups (p < 0.001), and between the 30 
nM and 100 nM treatment groups (p < 0.05) (Figure 4.11, A). 
 In the Moresco cell line, no inhibition of migration was noted after 24 hours of incubation 
with any of the evaluated Reparixin concentrations.  However, after 48 hr of incubation, 
significant increases in the percent of the acellular gap that was remaining were noted between 
the control and 100 nM treatment groups (p < 0.05), between the control and 300 nM treatment 
groups (p < 0.001), between the 30 nM and the 100 nM treatment groups (p < 0.01), and between 
the 30 nM and 300 nM treatment groups (p < 0.001) (Figure 4.11, B). 
 
4.7 IL-8 neutralization does not consistently affect migration in OS cell lines 
 Scratch assays with an IL-8 monoclonal antibody (mAb) were performed in the Gracie 
and Moresco cell lines to determine if IL-8 neutralization affects cellular migration.  After 24 hr 
of incubation, significant decreases in the percent of the acellular gap remaining between the 
control and 1 μg/mL IL-8 mAb treatment groups (p < 0.05) and between the 0.3 and 1 μg/mL IL-
8 mAb treatment groups (p < 0.01) in the Gracie cell line (Figure 4.12, A).  In the Moresco cell 
line, a significant increase in the percent acellular gap remaining was noted between the control 
40 
 
and 1 μg/mL IL-8 mAb treatment groups (p < 0.05) after 24 hr, and a significant decrease in 
percent gap remaining was observed between the 1 μg/mL and 3 μg/mL IL-8 mAb treatment 
groups (p < 0.05) (Figure 4.12, B). 
 
4.8 IL-8 receptor blockade does not sensitize OS cells to a platinum chemotherapeutic 
 To determine whether or not IL-8 blockade enhanced chemosensitivity, cell titer blue 
assays were performed in both the Gracie and the Moresco cell lines with varying doses of 
carboplatin and a fixed dose (100 nM) of Reparixin.  This fixed dose of Reparixin was chosen as 
it represents the IC50 of CXCR2, which is approximately 10 times greater than the IC50 of 
CXCR1.  Therefore, at this concentration of Reparixin, both IL-8 receptors should be effectively 
inhibited.  At 72 hr, no additive or synergistic effects were noted with the combination of 
Reparixin and varying doses of carboplatin in either the Gracie or Moresco cell line (Figure 4.13, 
A and B). 
 
4.9 IL-8 neutralization does not sensitize a low IL-8-producing cell line to a platinum 
chemotherapeutic 
 To determine whether or not IL-8 neutralization promoted chemosensitization to a 
platinum chemotherapeutic, cell titer blue assays were performed in the Moresco cell line with 
varying doses of carboplatin and a fixed dose of an IL-8 mAb (0.3 μg/mL).  This dose of IL-8 
mAb was chosen as effective neutralization was expected to be achieved given the hypothesized 
concentration of secreted IL-8 by Moresco at a fixed cellular density.  No significant synergistic 




4.10 Vascular endothelial growth factor (VEGF) expression is influenced by IL-8 in OS and a 
canine aortic endothelial cell line 
 Transcription of the VEGF gene was identified by qualitative PCR in the Gracie and 
Moresco cell line, as well as a canine aortic endothelial cell line (CnAoEC).  All three cell lines 
were incubated with IL-8 (10 ng/mL) or Reparixin (100 nM) for 24 hr and then VEGF gene 
transcription was reassessed.  An increase in VEGF gene transcript was observed in all cell lines 
after incubation with IL-8.  Though detectable, the VEGF gene transcript in the OS cells 
incubated with Reparixin was decreased when compared to transcript following incubation with 
IL-8 (Figure 4.15).  PCR could not be performed with CnAoEC incubated with Reparixin as 
incubation with this inhibitor appeared to cause decreased cell viability which limited our ability 






DISCUSSION AND CONCLUSIONS 
 IL-8 signaling plays an integral role in the modulation of the initial inflammatory 
response.  Specifically, IL-8 appears to be most important for regulating neutrophil chemotaxis 
and modulating neutrophil activity in response to inflammatory stimuli (31,33).  Aside from 
being a key regulator in physiologic inflammation, it is clear that IL-8 and its associated 
signaling axis play a key role in the development and progression of cancer.  In vitro, in a wide 
variety of cancers, IL-8 and IL-8 signaling has demonstrated several times over to promote 
cellular hallmarks requisite for successful metastasis, including increased proliferation, enhanced 
migration, chemoresistance, and angiogenesis (5).  Furthermore, in a clinical oncology setting, 
IL-8 is a well-established biomarker for a variety of solid tumors in people, with high serum IL-8 
or high intratumoral IL-8 typically serving as a negative prognostic indicator for disease free 
interval and overall survival (116,117).  Though inhibition of the IL-8 signaling axis in vitro 
typically results in successful mitigation of the pro-metastatic hallmarks, more work is needed in 
a clinical oncologic setting to determine how best to target IL-8.   
 There has been limited research investigating the role of IL-8 in cancers in veterinary 
species.  Dogs develop spontaneous cancers quite commonly, and many of these cancers serve as 
good models for human cancers.  OS is one such example.  Comparative genomic research has 
shown that IL-8 is expressed in canine patients with OS and that IL-8 expression is a negative 
prognostic factor for people with OS (22).  However, until this investigation, there has been no 
research devoted to determining how IL-8 potentially promotes metastasis in canine OS. 
 We were able to demonstrate mRNA expression of the IL-8 receptors, CXCR1 and 
CXCR2, in 6 different OS cell lines.  We also determined that protein expression for IL-8 and its 
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receptors were present in all of the cell lines.  Furthermore, we described concentration-
dependent secretion of IL-8 in 4 OS cells lines whose IL-8 production had never been previously 
investigated.  The demonstration of concurrent receptor expression and production of IL-8 by 
these cancer cells suggests a very likely autocrine or paracrine signaling in these OS cells.  
Autocrine/paracrine signaling has the potential to be highly advantageous to cancer cells.  
Aberrant and excessive production of signaling molecules by cancer cells that promote 
sustenance or progression can often overwhelm potential inhibitory stimuli and promote 
tolerance to an inhospitable tumor microenvironment.  
 Autocrine and/or paracrine IL-8 signaling in these OS cell lines likely plays a role in 
disease progression as the importance of IL-8 autocrine and/or paracrine signaling in 
tumorigenesis and metastasis has been documented several times over in human solid tumors.  
IL-8 signaling has been shown to upregulate genes necessary for epithelial-to-mesenchymal 
transition (EMT), a process considered essential for invasion and metastasis by solid, epithelial 
tumors (3,162).  In bladder cancer cell lines, it has been shown that autocrine IL-8 is essential for 
motogenesis in vitro (163). 
 After establishing the potential for autocrine/paracrine IL-8 signaling in OS cells, we 
sought to determine if manipulation of this signaling could promote features consistent with a 
potentially more metastatic phenotype.  Interestingly, addition of exogenous IL-8 to Moresco, 
the low IL-8-producing cell line, caused a significant dose-dependent increase in proliferation.  
However, increased proliferation was not observed in Gracie, an OS cell line that produces 
extraordinary amounts IL-8, with the addition of this chemokine to cell culture.  Based on this 
observation, we speculated that OS cells that secreted comparatively low amounts of IL-8 might 
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be more noticeably impacted by manipulation the IL-8 signaling axis should this signaling be a 
predominant driver in cellular features like proliferation and migration. 
 Though addition of exogenous IL-8 did impact proliferation, IL-8 receptor inhibition with 
Reparixin had no significant effect on proliferation in either Gracie or Moresco.  This lack of 
impact on proliferation was unexpected given that we were able to stimulate proliferation with 
addition of IL-8 to Moresco culture, especially with higher doses of Reparixin.  The theoretical 
IC50 of CXCR1 inhibition with Reparixin is 10 nM, whereas the IC50 of CXCR2 is reported to be 
100 nM.  Therefore, receptor signaling should have been entirely attenuated at the higher doses 
in the experimental range.  Assuming appropriate inhibition of IL-8’s cognate receptors, it is 
possible that upregulation of an alternate mitogenic signaling cascade led to sustained 
proliferation despite IL-8 signaling inhibition in these OS cell lines.  In order to prove this 
theory, a genome-wide survey (microarray analysis) of genes upregulated in response to 
treatment with Reparixin would likely be indicated.  One limitation to this study was that 
confirmation of Reparixin-CXCR1/CXCR2 binding was not confirmed.  Future work with this 
compound should incorporate research to confirm receptor binding.  Furthermore, determining 
whether or not Reparixin affects CXCR1/CXCR2 gene and protein expression, and, if so, 
determining the associated timeline of these transcriptional and translational changes is 
warranted. 
 We next investigated cellular proliferation in the two OS cell lines after exposure to a 
neutralizing IL-8 mAb.  Although no significant changes in proliferation were noted in the 
Moresco cell line after exposure to the IL- mAb after 24 hr, unexpectedly a significant increase 
in proliferation was noted between control conditions and the 1 and 3 μg/ml treatment 
conditions.  This finding, the opposite of what is intuitively expected, is difficult to explain.  
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Again, the upregulation of un-surveyed proliferation pathways may be able to explain the 
significant increases in proliferation in cell culture.  Similar to the additional research needed for 
Reparixin, further investigation into the IL-8 neutralization kinetics with this mAb would have 
been ideal to include in this body of work.  Specifically, determining how rapidly the mAb 
neutralizes IL-8 and its associated signaling and determining subsequent IL-8 secretion by OS 
cells following exposure to IL-8 mAb may help shed light on some of the unexpected findings 
with this product. 
 In addition to proliferation, we used scratch assays in the Gracie and Moresco cell lines to 
determine whether or not manipulation of the IL-8 signaling cascade affected migration in these 
OS cells.  In the Gracie cell line following 24 hr of incubation with varying dose of Reparixin, a 
significant increase in the percent of the acellular gap remaining between the control group and 
the 30 nM treatment group was noted.  However, after 48 hr, there was no significant difference 
between the control setting and the 30 nM treatment group.  Furthermore, significant decreases 
in the percent acellular gap remaining were noted between the control groups and the treatment 
groups with higher doses of Reparixin (100 and 300 nM) and between the 3 and 100 nM 
treatment groups.  These findings suggest that receptor inhibition likely have no prolonged or 
meaningful impact on cellular proliferation in this high IL-8-producing cell line.  In the Moresco 
cell line, no significant impact on migration was noted at 24 hr.  However, after 48 hr of 
incubation significant increases in the percent gap remaining were noted between the control and 
100 and 300 nM treatment groups, and between the 30 nM treatment group and the 100 and 300 
nM treatment groups.  This finding is suggestive that IL-8 receptor inhibition in this low-
producing cell line likely antagonizes cell migration.  We feel confident that this finding is a true 
reflection of an inhibited migration and not potentially secondary to Reparixin-induced 
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cytotoxicity as previous studies showed that Reparixin did not impact proliferation in Moresco.  
Again, using gene microarrays to evaluate genes in motogoenic pathways commonly upregulated 
in OS in people might be helpful in determining which intracellular signaling pathways are 
affected by IL-8 receptor inhibition and which pathways are persistently overly expressed despite 
IL-8 receptor inhibition. 
 The effects of IL-8 neutralization with the IL-8 mAb were also examined in the two OS 
cell lines at 24 hr.  In the Gracie cell line, we noted that migration was not successfully inhibited 
by the IL-8 mAb.  In the Moresco cell line, a trend towards a dose-dependent inhibition was 
observed in the 0.3 and 1 μg/mL treatment groups, but this same trend was not observed in the 3 
μg/ml.  Further investigation on the effects of IL-8 neutralization after longer exposure to the IL-
8 mAb is needed, as the neutralization time kinetics of this product are unknown. 
 Because IL-8 signaling has been proven several times over to promote chemoresistance 
in solid tumors in human cancer cell lines, we also sought to determine whether or not 
manipulation of the IL-8 signaling axis could affect sensitivity to a platinum chemotherapeutic.  
Incubation with the Gracie and Moresco cell lines with Reparixin at the IC50 of CXCR2 in 
combination with varying doses of carboplatin did not cause decreased cellular proliferation as 
compared to carboplatin alone.  We chose to extend our chemosensitivity studies to incorporate 
IL-8 neutralization with the mAb.  We only used the Moresco cell line to assess whether or not 
the IL-8 mAb promoted chemosensitization to carboplatin as the amount of antibody required to 
neutralize the amount of IL-8 produced by the Gracie cell line would have exceeded what was 
feasible for this study.  Again, at concentrations that should have far exceeded the amount 
necessary for IL-8 neutralization, the addition of the IL-8 mAb did not promote chemosensitvity 
in the Moresco cell line exposed to varying doses of carboplatin. 
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 There are several plausible explanations for our findings in our chemosensitization 
studies.  A simple explanation, assuming adequate inhibition of the IL-8 signaling axis, is that 
IL-8 signaling in these OS cell lines simply does not result in the transcription of genes involved 
in the cellular response to a cytotoxic agent.  Investigation into the expression of pro- or anti-
apoptotic proteins following manipulation of the IL-8 signaling axis in OS cell lines requires 
further investigation, and interpretation of these results may help explain the findings reported 
here.  It is also plausible to theorize that these two cell lines investigated might be comparatively 
inherently sensitive to carboplatin, and therefore, the effects of another agent that might modify 
the response to a potentially lethal agent may not be noted if the cell population is exquisitely 
sensitive to the lethal agent.  Therefore, it would be interesting to profile the chemosensitivity of 
carboplatin in several OS cell lines and to determine if alteration of the IL-8 signaling axis in 
those more inherently chemoresistant cells had a different effect than what was reported in our 
study. 
 Finally, because IL-8 has been shown to potentiate a pro-angiogenic tumor 
microenvironment, we performed a pilot study to examine the effects of manipulation of IL-8 
signaling on VEGF gene expression in our two OS cell lines and the CnAoEC.  In all cell lines 
we were able to demonstrate that incubation of cells with exogenous IL-8 led to increased VEGF 
gene transcript levels.  Inhibition of IL-8 signaling with Reparixin was able to decrease VEGF 
transcript to a level comparable to control conditions.  We were not able to demonstrate how 
Reparixin impacted VEGF expression in CnAoEC, as the addition of this receptor inhibitor to 
cell culture subjectively prevented proliferation.  Because of this, we have been unable to harvest 
adequate amounts of RNA and cDNA for analysis to date. 
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 The findings from this preliminary study are interesting and encouraging.  Determining 
the extent to which IL-8 promotes angiogenesis in OS cells or in the tumor microenvironment is 
warranted.  Promotion of angiogenesis might be the main mechanism through which IL-8 
promotes a more metastatic phenotype in OS, especially given that our research has shown that 
IL-8 and its associated signaling axis do not greatly impact proliferation or migration in these OS 
cell lines.  Future work in vitro should include the use of any of a variety of angiogenesis assays 
in order to determine if manipulating IL-8 signaling can influence angiogenesis.  Further studies 
investigating angiogenesis in vivo are also needed.  A simple study using immunohistochemical 
staining to determine IL-8 expression, VEGF expression, and intratumoral microvessel density to 
determine whether or not a correlation exists among these would be useful, and to the authors’ 
knowledge, no such study has been published. 
 Although IL-8 and its signaling axis do not seem to greatly impact proliferation, 
migration, and susceptibility to chemotherapy in vitro, it cannot be assumed that IL-8 signaling 
does not play in role in osteosarcoma progression and metastasis in vivo.  A pertinent example of 
how in vitro data does not always correlate well with in vivo results is brought to light in the 
research performed by Kim and colleagues (130).  Similar to our work, this group showed that 
addition of IL-8 or neutralization of IL-8 with a mAb did not impact proliferation or survival in 
canine hemangiosarcoma cell lines. However, in mouse xenograft experiments, tumor formation 
was significantly inhibited when mice were administered the IL-8 mAb as compared to controls.  
This finding, in combination with gene expression profiling data, led these investigators to 
conclude that IL-8 likely promotes an inflammatory tumor microenvironment which promotes 
tumor formation and progression.  Based on the results of this study, further investigation into 
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whether or not manipulation of the IL-8 axis in vivo promotes OS tumor formation and 
metastasis. 
 In conclusion, we were able to show that OS cell lines express IL-8’s cognate receptors, 
CXCR1 and CXCR2, and that these cell lines secrete IL-8 in a concentration dependent manner.  
We were also able to show that the addition of exogenous IL-8 promotes proliferation in an OS 
cell line that is a low-producer of IL-8 (Moresco).  However, IL-8 receptor inhibition and IL-8 
neutralization had no impact on OS cell proliferation.  Although receptor inhibition did not affect 
proliferation, receptor inhibition did inhibit cellular migration in a dose-dependent fashion in the 
Moresco cell line.  Neutralization of IL-8 with a mAb had no significant impact on migration 
these OS cell lines.  Chemosensitization to a platinum chemotherapy agent was not achieved 
with either IL-8 receptor blockade or IL-8 neutralization.  However, addition of IL-8 to cell 
culture did enhance VEGF gene transcription in the OS cell lines and a canine endothelial cell 
line.  Therefore, we conclude that IL-8 signaling may play a role in promoting proliferation and 
migration in those OS cell lines that produce low amounts of IL-8.  We hypothesize that IL-8 
may promote its most potent pro-metastatic effects by encouraging a pro-angiogenic tumor 
microenvironment.  Future studies investigating changes in gene expression profiles with 
manipulation of IL-8 signaling, investigating manipulation of IL-8 signaling in vivo, and 
investigating IL-8, IL-8 signaling, and the tumor microenvironment in canine OS are warranted 







Figure 4.1 Reverse-transcriptase polymerase chain reaction (RT-PCR) for CXCR1 and CXCR2 
gene transcription. Amplicons generated by RT-PCR for the CXCR1 and CXCR2 genes (top 
panels) and the house-keeping gene, GADPH (lower panels). Respective OS cell lines evaluated 
as indicated.   
 
 
Figure 4.2 Western blot for IL-8 in 6 different OS cell lines.  β actin is used as a positive control 





Figure 4.3 Western blot for CXCR1 in 6 different OS cell lines.  β actin is used as a positive 
control for adequate protein loading.   
 
Figure 4.4 Western blot for CXCR2 in 6 different OS cell lines.  β actin is used as a positive 







Figure 4.5 Results of an IL-8 ELISA showing that IL-8 is secreted by OS cells in a cell density-
dependent manner.  
 
Figure 4.6 Results of an IL-8 ELISA with the McKinley, Moresco, and Vogel OS cell lines 





Figure 4.7 The comparison between IL-8 secretion between our “high producer” OS cell line, 








Figure 4.8 Cell Titer Blue assays were used to assess differences in cellular proliferation 
following 72 hr incubation with varying concentrations of exogenous IL-8 in the Gracie (A) and 








Figure 4.9   Cell Titer Blue assays were used to assess differences in cellular proliferation 
following 72 hr incubation with varying concentrations of the CXCR1 and CXCR2 inhibitor, 







Figure 4.10  Cell Titer Blue assays were used to assess differences in cellular proliferation 
following 72 hr incubation with varying concentrations of an IL-8 blocking mAb in the Gracie 







Figure 4.11  Scratch assays were used to assess cellular migration at 24 and 48 hr in the Gracie 
(A) and Moresco (B) cell lines following treatment with Reparixin at varying concentrations.  * p 








Figure 4.12 Scratch assays were used to assess cellular migration at 24 hr in the Gracie (A) and 
Moresco (B) cell lines following treatment with an IL-8 blocking mAb at varying concentrations.  








Figure 4.13 Cell Titer Blue assays were used to assess differences in cellular proliferation 
following 72 hr incubation with the combination of Reparixin at a fixed, sufficiently inhibitory 








Figure 4.14 Cell Titer Blue assays were used to assess differences in cellular proliferation 
following 72 hr incubation with the combination of Reparixin at a fixed, sufficiently inhibitory 







Figure 4.15  RT-PCR for VEGF gene transcription. Amplicons generated by RT-PCR for the 
VEGF gene (top panels) and the house-keeping gene, GADPH (lower panels) in two OS cell 
lines (Gracie and Moresco) and canine aortic endothelial cell line (CnAoEC).  All cell lines were 
incubated for 24 hr with exogenous IL-8 at 10 ng/ml.  As a separate treatment, cell lines were 
incubated with Reparixin at 100 nM.  Following Reparixin treatment, only sufficient quantities 
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